Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.64 |
| ▸ | HTR3B | O95264 | 3/20 | 0.64 |
| ▸ | HTR3A | P46098 | 3/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809857 | 0.82 | GRIN2D (0.57) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL465738 | 0.82 | GRIN2D (0.57) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6242154 | 0.81 | HTR3E (0.68) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2253010 | 0.81 | GRIN2D (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2252097 | 0.81 | GRIN2D (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL28876577 | 0.79 | GRIN2D (0.54) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL23770804 | 0.78 | HTR3E (0.64) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3154750 | 0.78 | HTR3A (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2586058 | 0.78 | HTR3E (0.64) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL615260 | 0.78 | HTR3E (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-102659774-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE | 2012-09-12 | — | — | CN | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101282972-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | HTR3E 71/4885HTR3B 68/4885HTR3A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.